CAPTRUST Financial Advisors
ANTX icon

CAPTRUST Financial Advisors’s AN2 Therapeutics ANTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
40,165
+165
+0.4% +$710 ﹤0.01% 2895
2026
Q1 		$137K Hold
40,000
– – ﹤0.01% 2757
2025
Q4 		$45.6K Hold
40,000
– – ﹤0.01% 2686
2025
Q3 		$50.8K Hold
40,000
– – ﹤0.01% 2562
2025
Q2 		$42.4K Buy
40,000
+30,000
+300% +$35.8K ﹤0.01% 2442
2025
Q1 		$13.6K Sell
10,000
-18,667
-65% -$23.5K ﹤0.01% 2330
2024
Q4 		$39.6K Hold
28,667
– – ﹤0.01% 2251
2024
Q3 		$30.7K Hold
28,667
– – ﹤0.01% 2256
2024
Q2 		$61.6K Hold
28,667
– – ﹤0.01% 2136
2024
Q1 		$93.2K Hold
28,667
– – ﹤0.01% 2065
2023
Q4 		$587K Hold
28,667
– – ﹤0.01% 1634
2023
Q3 		$461K Buy
+28,667
New +$325K ﹤0.01% 1696

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

CAPTRUST Financial Advisors's ANTX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its AN2 Therapeutics (ANTX) stake by 0.41% in Q2 2026, buying an estimated $710 and bringing the position to 40,165 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

CAPTRUST Financial Advisors first reported a position in ANTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $587K in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • CAPTRUST Financial Advisors held 40,165 shares of AN2 Therapeutics worth $194K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 165 AN2 Therapeutics shares in Q2 2026, an estimated $710.
  • AN2 Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2895 holding.
  • CAPTRUST Financial Advisors first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • CAPTRUST Financial Advisors's AN2 Therapeutics position peaked at $587K in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.